IP Library › Granted Patent US 12,270,809
Granted Patent B2
US 12,270,809 · App. 17/508,742 · Granted Apr 8, 2025

Method for the site-specific covalent cross-linking of antibodies to surfaces

Inventors: Andrew Tsourkas (Bryn Mawr, PA); James Z Hui (Philadelphia, PA)
Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
G01N33/54353A61K47/62A61K47/65A61K47/6855A61K49/1875C07K14/31C07K17/00C07K17/06G01N33/582C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,270,809
App. No.
17/508,742
Granted
Apr 8, 2025
Kind
B2
Abstract

This invention relates to conjugate antibody, drug and nanoparticle compositions and methods of generating the same. This invention further relates to methods of using same for imaging, diagnosing or treating a disease.

Claims (25)

1. A conjugate composition comprising a variant of protein Z comprising a photoreactive crosslinker that permits specific binding to an immunoglobulin Fc region, wherein the variant of protein Z comprises an amino acid sequence about sixty-one amino acids in length and which has at least 80% identity to the sequence set forth in SEQ ID NO: 1 with the photoreactive crosslinker substituted for or introduced at F13, Q32, K35, N28, N23, or L17.

2. The composition of claim 1 , wherein said immunoglobulin is IgG.

3. The composition of claim 1 , wherein said photoreactive crosslinker is a UV-active non-natural amino acid.

4. The composition of claim 3 , wherein said amino acid is benzoylphenylalaine (BPA).

5. The composition of claim 1 , wherein said composition comprises a fusion protein comprising the variant of protein Z fused to an additional polypeptide.

6. The composition of claim 5 , wherein said fusion protein further comprises a moiety for expressed protein ligation.

7. The composition of claim 6 , wherein said moiety is an intein-MPB group or a sortase-His×6 group.

8. The composition of claim 1 , wherein said variant of protein Z is attached to a peptide following an expressed protein ligation.

9. The composition of claim 8 , wherein said peptide is attached to an additional polypeptide of interest via a crosslinker.

10. The composition of claim 8 , wherein said peptide comprises a chemical moiety that permits chemical binding to a corresponding chemical group.

11. The composition of claim 10 , wherein said chemical binding is click chemistry or maleimide chemistry.

12. The composition of claim 8 , wherein said variant of protein Z is specifically attached in the proper orientation to a surface, polypeptide, a nanoparticle, or a drug via said click chemistry.

13. The composition of claim 9 , wherein said additional polypeptide is a drug, an imaging agent, or a toxin.

14. A bacterial cell for recombinantly expressing the composition of claim 8 .

15. A bacterial cell for recombinantly expressing the composition of claim 1 .

16. A nanoparticle conjugate comprising the composition of claim 1 .

17. A modified antibody complex comprising the composition of claim 1 .

18. The modified antibody complex of claim 17 , comprising a drug-antibody combination.

19. A method of imaging a biological sample, the method comprising the step of contacting said biological sample with the nanoparticle conjugate of claim 16 , wherein said contacting permits imaging of said biological sample.

20. A method of imaging a biological sample, the method comprising the step of contacting a biological sample with said antibody complex of claim 17 , wherein said contacting permits imaging of said biological sample.

21. The method of claim 19 , wherein said biological sample is associated with a disease.

22. The method of claim 21 , wherein imaging said biological sample permits diagnosing a disease.

23. The method of claim 21 , wherein said biological sample is tissue, DNA, sperm, sera, blood, cerebrospinal fluid, or a biomarker.

24. A method of producing the conjugate composition of claim 1 , the method comprising the step of recombinantly expressing said conjugate composition in a bacterial cell.

25. The composition of claim 4 , wherein the variant is K35BPA or L17BPA.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 25, 2021
From: TSOURKAS, ANDREW; HUI, JAMES Z.
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 057898/0332 →
Continuity (3)
Continuation 14774883
Provisional Application 61800926 · Mar 15, 2013
Related Publication 20220214337A1 · Jul 7, 2022
References Cited (29)
US 3773919A · Boswell et al. · 1973 [cited by applicant]
US 4485045A · Regen · 1984 [cited by applicant]
US 4544545A · Ryan et al. · 1985 [cited by applicant]
US 5013556A · Woodle et al. · 1991 [cited by applicant]
US 8916689B2 · Hober et al. · 2014 [cited by applicant]
US 11156608B2 · Tsourkas · 2021 [cited by examiner]
US 20030082575A1 · Schultz et al. · 2003 [cited by applicant]
US 20140249296A1 · Ploegh et al. · 2014 [cited by applicant]
US 20160032346A1 · Tsourkas et al. · 2016 [cited by applicant]
WO WO199738731 · 1997 [cited by applicant]
WO WO2005051976 · 2005 [cited by applicant]
WO WO2012033446 · 2012 [cited by applicant]
WO WO2014145441 · 2014 [cited by applicant]
WO WO2014145654 · 2014 [cited by applicant]
Cedergren et al., “Mutational analysis of the interaction between staphylococcal protein A and human IgG1.” Protein Engineering, vol. 6(4); pp. 441-448, Jun. 1993. [cited by applicant]
Chari et al., “Immunoconjugates containing novel maytansinoids: promising anticancer drugs”, Cancer Research 1992,52: 127-131. [cited by applicant]
Elias et al., “An Intein-Medicated Site-Specific Click Conjugation Strategy for Improved Tumor Targeting of Nanoparticle Systems”. Small 2010, Nov. 5, vol. 6 (21), pp. 2460-2468. [cited by applicant]
Eppstein et al., “Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor”, Proc. Natl. Acad. Sci. 1985, 82:3688. [cited by applicant]
Gabizon et al., “Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times”, J. National Cancer Inst. 1989,81: 1484. [cited by applicant]
Guo et al, “Protein tolerance to random amino acid change” 2004, Proc. Natl. Acad. Sci. USA 101: 9205- 9210. (Year: 2004). [cited by applicant]
Hui et al., Facile Method for the site-specific, covalent attachment of full-length IgG onto nanoparticles, Small 2014, pp. 1-10. [cited by applicant]
Hui et al., “Optimization of photoactive protein Z for the fast and efficient site-specific conjugation of native IgG.” Aug. 2014. 27:; 25(9): 1709-19. [cited by applicant]
Hwang et al., “Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterolliposomes: a kinetic study”, Proc. Natl. Acad. Sci. 1980, 77:4030. [cited by applicant]
Perols et al., “Stite-specific photoconjugation of antibodies using chemically synthesized IgG-binding domains”. Bioconjugate chemistry. Feb. 25, 2014;25(3):481-8. [cited by applicant]
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity” Proc Natl Acad Sci USA vol. 79 pp. 1979-1983 (Year: 1982). [cited by applicant]
Stahl et al., “The use of gene fusions to protein A and protein G in immunology and biotechnology”, Pathol. Biol. 1997, vol. 45, No. 1, pp. 66-76. [cited by applicant]
Stella et al., “Prodrugs: A Chemical Approach to Targeted Drug Delivery”, in Directed Drug Delivery, Borchardt et al., 247-267, Humana Press 1985. [cited by applicant]
Wagner et al., “Bispecific antibody generated with sortase and click chemistry has broad antiinfluenza virus activity.” Proceedings of he National Academy of Sciences. Nov. 25, 2014;111(47):16820-5. [cited by applicant]
Willman, “Biochemical Society Transactions, 1986, 615” Meeting Belfast, 14: 375-382. [cited by applicant]